AKERO THERAPEUTICS INC (AKRO) Stock Earnings & Estimates
USA - NASDAQ:AKRO - US00973Y1082 - Common Stock
45.22 USD
-0.98 (-2.12%)
45.22 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 364.47% | N/A 113.87% | N/A 72.40% | N/A -9.89% | |||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | -80.13M -73.23% | -100.85M -25.86% | -115.12M -14.15% | -172.841M -50.14% | -285.405M -65.13% | N/A -23.22% | N/A -12.59% | N/A -16.86% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.56M | -13.78M -202.19% | -45.65M -231.28% | -80.15M -75.58% | -100.89M -25.88% | -115.16M -14.14% | -172.87M -50.11% | -285.423M -65.11% | N/A -18.81% | N/A -13.41% | N/A -18.69% | N/A 51.22% | N/A 206.30% | N/A 296.08% | N/A 113.12% | N/A -46.85% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.48 13.42% | -2.89 -16.53% | -2.92 -1.04% | -2.85 2.40% | -3.75 -31.58% | N/A -1.56% | N/A -18.09% | N/A -13.85% | N/A 90.24% | N/A 1,285.71% | N/A 180.21% | N/A 84.71% | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.94 10.87% | -0.97 2.12% | -0.99 -10.50% | -1.02 -18.31% | -1.07 -14.44% | -1.10 -13.68% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | -88.414M -8.22% | -91.484M -17.28% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -85.174M -4.25% | -87.59M -12.26% | -88.026M -8.83% | -91.239M -12.82% | -94.962M -11.49% | -98.022M -11.91% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.86 -6.17% | -0.91 | 0.05 | 5.55% |
| Q1 2025 Q2Q % growth | -0.90 | -0.99 | 0.09 | 9.09% |
| Q4 2024 Q2Q % growth | -0.99 | -1.18 | 0.19 | 15.77% |
| Q3 2024 Q2Q % growth | -1.05 -47.89% | -0.92 | -0.13 | -13.96% |
| Q2 2024 Q2Q % growth | -0.81 -35.00% | -0.92 | 0.11 | 11.64% |
| Q1 2024 Q2Q % growth | -0.90 -63.64% | -0.97 | 0.07 | 7.40% |
| Q4 2023 Q2Q % growth | -0.99 -102.04% | -0.88 | -0.11 | -12.70% |
| Q3 2023 Q2Q % growth | -0.71 22.83% | -0.69 | -0.02 | -2.18% |
| Q2 2023 Q2Q % growth | -0.60 22.08% | -0.64 | 0.04 | 6.33% |
| Q1 2023 Q2Q % growth | -0.55 25.68% | -0.69 | 0.14 | 19.76% |
| Q4 2022 Q2Q % growth | -0.49 47.31% | -0.81 | 0.32 | 39.80% |
| Q3 2022 Q2Q % growth | -0.92 -31.43% | -0.75 | -0.17 | -22.22% |
| Q2 2022 Q2Q % growth | -0.77 7.23% | -0.87 | 0.10 | 11.81% |
| Q1 2022 Q2Q % growth | -0.74 -72.09% | -0.81 | 0.07 | 9.09% |
| Q4 2021 Q2Q % growth | -0.93 -8.14% | -0.83 | -0.10 | -11.42% |
| Q3 2021 Q2Q % growth | -0.70 -11.11% | -0.93 | 0.23 | 24.59% |
| Q2 2021 Q2Q % growth | -0.83 -45.61% | -0.74 | -0.09 | -12.50% |
| Q1 2021 Q2Q % growth | -0.43 -2.38% | -0.93 | 0.50 | 53.60% |
| Q4 2020 Q2Q % growth | -0.86 -56.36% | -0.60 | -0.26 | -42.56% |
| Q3 2020 Q2Q % growth | -0.63 -12.50% | -0.66 | 0.03 | 4.49% |
| Q2 2020 Q2Q % growth | -0.57 74.21% | -0.63 | 0.06 | 9.87% |
| Q1 2020 Q2Q % growth | -0.42 | -0.62 | 0.20 | 32.72% |
| Q4 2019 Q2Q % growth | -0.55 | -0.60 | 0.05 | 8.30% |
| Q3 2019 Q2Q % growth | -0.56 | -0.44 | -0.12 | -27.68% |
| Q2 2019 Q2Q % growth | -2.21 | -0.37 | -1.84 | -496.34% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 2.79% | 5.83% | 0% | 3.66% |
| Revenue | N/A | N/A | N/A | N/A |